To identify the genes whose repression affects the responsiveness of breast cancer cells to PARP inhibitors, we conducted a genome-wide CRISPR dCas9 interference screen in the TNBC cell line MDA-MB-468 in the presence of olaparib. Here, PARP1 is linked to breast carcinoma.